Hosts Terry Turner and Whitney Ray Di Bona unpack how companies plan for legal risk long before products reach patients — from trial design and FDA strategy to marketing, lobbying and bankruptcy maneuvers like Johnson & Johnson’s failed “Texas Two-Step” talc strategy.
The episode features investigative reporters Shannon Brownlee and Jeanne Lenzer on how drugmakers shape the evidence behind approvals. Cardiologist Dr. Peter Kowey weighs in on the profit motives that influence research and prescribing, while whistleblower advocate Louis Clark discusses the legal pressure companies use to silence critics. Former pharma insider William Soliman talks about how litigation, compliance and transparency factor into every launch.
It’s a look at how Big Pharma's profits and lawsuits are often linked from the very start.
Podden och tillhörande omslagsbild på den här sidan tillhör
Drugwatch.com. Innehållet i podden är skapat av Drugwatch.com och inte av,
eller tillsammans med, Poddtoppen.
